^
    Contact us  to learn more about
    our Premium Content:  News alerts, weekly reports and conference planners

    TEST:
    MRDVision

    Company:
    Inocras
    Type:
    Laboratory Developed Test
    Related tests:

    Details

    Evidence
    News
    MRDVision is a minimal residual disease (MRD) detection solution showcasing a limit of detection (LOD) down to one-in-a-million. MRDVision combines Inocras’s WGS cancer profiling platform, CancerVision, and Ultima Genomics’ ppmSeq™ technology to deliver high-accuracy detection of circulating tumor DNA. This assay offers a low limit of detection, straightforward workflow, and fast turnaround time, all at a low cost.
    Method:
    Whole-genome sequencing (WGS)